Skip to content

Permanent Supportive Housing Overdose Prevention+ Study

Preventing Overdose in Supportive Housing: Stepped Wedge Randomized Controlled Trial of a Multi-Sector, Upstream Intervention

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07214519
Acronym
POP+
Enrollment
2940
Registered
2025-10-09
Start date
2027-07-01
Completion date
2031-03-31
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overdose, Substance Use

Brief summary

This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.

Detailed description

Homelessness and housing instability are strongly linked with overdose risk. Permanent supportive housing (PSH) -subsidized housing paired with supportive services-is a key strategy to end homelessness yet supportive housing tenants face high overdose risk due to a confluence of factors. This multi-sector, community-partnered, stepped wedge randomized controlled trial evaluates the impact of a technical assistance intervention designed to support supportive housing agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly. The technical assistance intervention will be delivered to supportive housing agencies in New Jersey and New York who are enrolled in the trial. Outcomes include PSH agency implementation of overdose prevention practices and downstream tenant overdose, substance use, and other health-related outcomes. Outcomes will be assessed using surveys, administrative data, and agency records. This trial is a part of the HEAL Initiative (https://heal.nih.gov/).

Interventions

BEHAVIORALTA Intervention

Technical assistance (TA) intervention designed to support PSH agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly.

Sponsors

NYU Langone Health
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

We will be enrolling supportive housing agencies from NY and NJ to participate in this study. Trial enrollment and intervention delivery will occur at the level of the agency. There are anticipated to be 24 supportive housing agencies total that will be enrolled in the study; approximately 6 agencies will be randomly assigned to each of the four intervention waves in the stepped wedge randomized controlled trial. Inclusion Criteria: Supportive Housing Agencies/Individuals who Work at Supportive Housing Agencies: * Serve at least 40 tenants in New York and/or New Jersey * Have a significant concern for overdose (as demonstrated by past year tenant overdose) * Be willing to complete all activities required for participation in the trial Tenants who Live in Supportive Housing Agencies: * Must live in an enrolled Supportive Housing Agency * Must be 18 years and older

Exclusion criteria

* See inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Composite Score of Agency-Level Fidelity to Overdose Prevention Evidence-Based PracticesBaseline, Month 12 (End of Wave 1), Month 19 (End of Wave 2), Month 26 (End of Wave 3), Month 33 (End of Wave 4)Fidelity will be measured as the extent to which an intervention is implemented as intended by researchers; the specific method of measurement will be determined during the trial's preparatory phase, in consultation with multiple stakeholders. The measurement will comprise a composite score of multiple measures.

Countries

United States

Contacts

CONTACTKelly Doran, MD
Kelly.Doran@nyulangone.org212-263-5850
PRINCIPAL_INVESTIGATORKelly Doran, MD

NYU Langone Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026